

Reimbursement Policy

Testing for Diagnosis of Active or Latent Tuberculosis

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Infection by *Mycobacterium tuberculosis* (Mtb) results in a wide range of clinical presentations dependent upon the site of infection from classic signs and symptoms of pulmonary disease (cough greater than two to three weeks' duration, lymphadenopathy, fevers, night sweats, weight loss) to silent infection with a complete absence of signs or symptoms.¹

Culture of Mtb is the gold standard for diagnosis as it is the most sensitive and provides an isolate for drug susceptibility testing and species identification.² Nucleic acid amplification tests (NAAT) use polymerase chain reactions (PCR) to enable sensitive detection and identification of low-density infections.³ Interferon-gamma release assays (IGRAs) are blood tests of cell-mediated immune response which measure T-cell release of interferon (IFN)-gamma following stimulation by specific antigens such as *Mycobacterium tuberculosis* antigens^{1,4} used to detect a cellular immune response to *M. tuberculosis* which would indicate latent tuberculosis infection (LTBI).⁵

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) To diagnose or screen for latent tuberculosis (TB) infection, an interferon gamma release assay (IGRA) **MEETS COVERAGE CRITERIA** in:
 - a) Individuals who are at risk for infection with *Mycobacterium tuberculosis* (Mtb).
 - b) Individuals who are unlikely to be infected with Mtb when screening is obliged by law.
- 2) For all suspected TB infections, the following tests **MEET COVERAGE CRITERIA**:
 - a) Acid fast bacilli (AFB) smear/stain.
 - b) Culture and culture-based drug susceptibility testing of *Mycobacteria* spp.

Reimbursement Policy

- c) Qualitative nucleic acid amplification testing (NAAT) for *Mycobacteria* spp., *M. tuberculosis*, and *M. avium* complex.
- 3) For individuals whose sputum is AFB smear positive or NAAT positive, molecular-based drug susceptibility testing **MEETS COVERAGE CRITERIA** when **one** of the following criteria is met:
 - a) The individual has been treated for TB in the past.
 - b) The individual was born in or has lived for at least 1 year in a foreign country with at least a moderate TB incidence (≥ 20 per 100,000) or a high primary multi-drug resistant (MDR)-TB prevalence ($\geq 2\%$).
 - c) The individual is a contact of an individual with MDR-TB.
 - d) The individual is HIV infected.
- 4) Repeat drug susceptibility testing **MEETS COVERAGE CRITERIA** in **any** of the following situations:
 - a) For individuals whose sputum cultures remain positive after 3 months of treatment.
 - b) When there is bacteriological reversion from negative to positive.
- 5) For individuals with pleural effusion, pericardial effusion, or ascites and suspected TB infection, cell counts, protein, glucose, and lactate dehydrogenase (LDH) concentrations of cerebrospinal, pleural, peritoneal, pericardial, and other fluids **MEETS COVERAGE CRITERIA**.
- 6) In HIV-infected individuals with CD4 cell counts ≤ 100 cells/microL who have signs and symptoms of tuberculosis, urine-based detection of mycobacterial cell wall glycolipid lipoarabinomannan (LAM) **MEETS COVERAGE CRITERIA**.
- 7) For individuals with active tuberculosis, IGRA **DOES NOT MEET COVERAGE CRITERIA**.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 8) Quantitative nucleic acid testing for *Mycobacterium* spp, *M. tuberculosis*, and *M. avium* complex **DOES NOT MEET COVERAGE CRITERIA**.
- 9) Whole genome sequencing of *Mycobacterium* spp. for the detection of drug resistance **DOES NOT MEET COVERAGE CRITERIA**.

Reimbursement Policy

- 10) Genotyping of *Mycobacterium* spp. **DOES NOT MEET COVERAGE CRITERIA.**
- 11) Testing of adenosine deaminase (ADA) and interferon-gamma (IFN- γ) levels in cerebrospinal, pleural, peritoneal, pericardial, and other fluids for the diagnosis of extrapulmonary TB **DOES NOT MEET COVERAGE CRITERIA.**
- 12) Testing of serum protein biomarkers or panels of biomarkers for the detection and diagnosis of TB **DOES NOT MEET COVERAGE CRITERIA.**

III. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

IV. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
81479	Unlisted molecular pathology procedure
82945	Glucose, body fluid, other than blood
83615	Lactate dehydrogenase (LD), (LDH);
84157	Protein, total, except by refractometry; other source (e.g., synovial fluid, cerebrospinal fluid)
84311	Spectrophotometry, analyte not elsewhere specified
86480	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
86481	Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension
87070	Culture, bacterial; any other source except urine, blood, or stool, aerobic, with isolation and presumptive identification of isolates

Reimbursement Policy

CPT	Code Description
87077	Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate
87116	Culture, tubercle, or other acid-fast bacilli (e.g., TB, AFB, mycobacteria) any source, with isolation and presumptive identification of isolates
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed
87153	Culture, typing; identification by nucleic acid sequencing method, each isolate (e.g., sequencing of the 16S rRNA gene)
87181	Susceptibility studies, antimicrobial agent; agar dilution method, per agent (e.g., antibiotic gradient strip)
87184	Susceptibility studies, antimicrobial agent; disk method, per plate (12 or fewer agents)
87185	Susceptibility studies, antimicrobial agent; enzyme detection (e.g., beta lactamase), per enzyme
87186	Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate
87187	Susceptibility studies, antimicrobial agent; microdilution or agar dilution, minimum lethal concentration (MLC), each plate (List separately in addition to code for primary procedure)
87188	Susceptibility studies, antimicrobial agent; macrobroth dilution method, each agent
87190	Susceptibility studies, antimicrobial agent; mycobacteria, proportion method, each agent
87206	Smear, primary source with interpretation; fluorescent and/or acid-fast stain for bacteria, fungi, parasites, viruses, or cell types
87551	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique
87552	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, quantification
87556	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique
87557	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, quantification
87561	Infectious agent detection by nucleic acid (DNA or RNA); mycobacteria avium-intracellulare, amplified probe technique
87562	Infectious agent detection by nucleic acid (DNA or RNA); mycobacteria avium-intracellulare, quantification

Reimbursement Policy

CPT	Code Description
87564	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, rifampin resistance, amplified probe technique
0574U	Mycobacterium tuberculosis, culture filtrate protein–10-kDa (CFP-10), serum or plasma, liquid chromatography mass spectrometry (LC-MS) Proprietary test: NanoDetect-TB™ Lab/Manufacturer: NanoPin Technologies, Inc

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Evidence-based Scientific References

1. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. Jan 15 2017;64(2):111-115. doi:10.1093/cid/ciw778
2. Bernardo J. Diagnosis of pulmonary tuberculosis in adults. Updated August 29, 2025. <https://www.uptodate.com/contents/diagnosis-of-pulmonary-tuberculosis-in-adults>
3. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM, Jr. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. *BMC infectious diseases*. 2004;4:6. doi:10.1186/1471-2334-4-6
4. Menzies D. Use of interferon-gamma release assays for diagnosis of latent tuberculosis infection (tuberculosis screening) in adults. Updated July 23, 2025. <https://www.uptodate.com/contents/use-of-interferon-gamma-release-assays-for-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults>
5. Pai M, Denking CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. *Clinical microbiology reviews*. 2014;27(1):3-20. doi:10.1128/cmr.00034-13
6. WHO. *Global tuberculosis report 2024*. World Health Organization; 2024. <https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1>
7. Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. *The Lancet Respiratory medicine*. Apr 2014;2(4):321-38. doi:10.1016/s2213-2600(14)70031-1
8. Heemskerk D, Caws M, Marais B, Farrar J. Clinical Manifestations. *Tuberculosis in Adults and Children*. Springer; 2015.
9. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. *Clinical infectious diseases :*

Reimbursement Policy

- an official publication of the Infectious Diseases Society of America.* 2009;49(9):1350-7.
doi:10.1086/605559
10. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. *Respirology (Carlton, Vic)*. 2010;15(3):433-50.
doi:10.1111/j.1440-1843.2010.01739.x
 11. Barry CE, 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. *Nature reviews Microbiology*. 2009;7(12):845-55.
doi:10.1038/nrmicro2236
 12. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. Dec 2008;12(12):1352-64.
 13. ATS. Targeted tuberculin testing and treatment of latent tuberculosis infection. . *American journal of respiratory and critical care medicine*. Apr 2000;161(4 Pt 2):S221-47.
doi:10.1164/ajrccm.161.supplement_3.ats600
 14. FDA. Summary of Safety and Effectiveness Data.
https://www.accessdata.fda.gov/cdrh_docs/pdf/p010033b.pdf
 15. Daniel TM. The immunology of tuberculosis. *Clinics in chest medicine*. 1980;1(2):189-201.
 16. Francis J, Seiler RJ, Wilkie IW, O'Boyle D, Lumsden MJ, Frost AJ. The sensitivity and specificity of various tuberculin tests using bovine PPD and other tuberculins. *The Veterinary record*. 1978;103(19):420-5.
 17. Katial RK, Hershey J, Purohit-Seth T, et al. Cell-Mediated Immune Response to Tuberculosis Antigens: Comparison of Skin Testing and Measurement of In Vitro Gamma Interferon Production in Whole-Blood Culture. *Clin Diagn Lab Immunol*. 2001;8(2):339-45.
doi:10.1128/cdli.8.2.339-345.2001
 18. Fenton MJ, Vermeulen MW, Kim S, Burdick M, Strieter RM, Kornfeld H. Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. *Infection and immunity*. 1997;65(12):5149-56.
 19. Lein AD, Von Reyn CF. In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. *The American journal of the medical sciences*. Jun 1997;313(6):364-71.
 20. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Annals of internal medicine*. 2007;146(5):340-54.
 21. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. *Chest*. 2012;142(1):63-75. doi:10.1378/chest.11-3157
 22. Ruan Q, Zhang S, Ai J, Shao L, Zhang W. Screening of latent tuberculosis infection by interferon-gamma release assays in rheumatic patients: a systemic review and meta-analysis. *Clinical rheumatology*. 2016;35(2):417-25. doi:10.1007/s10067-014-2817-6

Reimbursement Policy

23. Auguste P, Tsertsivadze A, Pink J, et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. *BMC infectious diseases*. 2017;17(1):200. doi:10.1186/s12879-017-2301-4
24. Nasiri MJ, Pormohammad A, Goudarzi H, et al. Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA. *Infection*. 2019;47(3):353-361. doi:10.1007/s15010-019-01285-7
25. Khanna U, Ellis A, Gallop J, Galadari A, Hu J, Fernandez AP. AB008. Utility of repeat latent tuberculosis testing in patients with immune-mediated diseases taking biologics. *Ann Transl Med*. Mar 2021;9(5)doi:10.21037/atm.2021.AB008
26. Neema S, Radhakrishnan S, Dabbas D, Vasudevan B. Latent Tuberculosis in Psoriasis Patients Planned for Systemic Therapy - A Prospective Observational Study. *Indian Dermatol Online J*. 2021;12(3):429-432. doi:10.4103/idoj.IDOJ_698_20
27. Ren W, Ma Z, Li Q, et al. Antigen-specific chemokine profiles as biomarkers for detecting Mycobacterium tuberculosis infection. *Front Immunol*. 2024;15:1359555. doi:10.3389/fimmu.2024.1359555
28. Pai M, Nicol MP, Boehme CC. Tuberculosis Diagnostics: State of the Art and Future Directions. *Microbiology spectrum*. 2016;4(5)doi:10.1128/microbiolspec.TBTB2-0019-2016
29. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. May 2007;11(5):485-95.
30. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. *The Lancet Infectious diseases*. 2006;6(10):664-74. doi:10.1016/s1473-3099(06)70602-8
31. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. *The Lancet Infectious diseases*. 2006;6(9):570-81. doi:10.1016/s1473-3099(06)70578-3
32. Gordin F, Slutkin G. The validity of acid-fast smears in the diagnosis of pulmonary tuberculosis. *Archives of pathology & laboratory medicine*. 1990;114(10):1025-7.
33. Yajko DM, Nassos PS, Sanders CA, Madej JJ, Hadley WK. High predictive value of the acid-fast smear for Mycobacterium tuberculosis despite the high prevalence of Mycobacterium avium complex in respiratory specimens. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 1994;19(2):334-6.
34. Greco S, Girardi E, Navarra A, Saltini C. Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. *Thorax*. 2006;61(9):783-90. doi:10.1136/thx.2005.054908
35. Cheng VC, Yew WW, Yuen KY. Molecular diagnostics in tuberculosis. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2005;24(11):711-20. doi:10.1007/s10096-005-0039-1

Reimbursement Policy

36. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. *PloS one*. Feb 6 2008;3(2):e1536. doi:10.1371/journal.pone.0001536
37. CDC. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. *MMWR Morbidity and mortality weekly report*. 2009;58(1):7-10.
38. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports*. 2005;54(Rr-12):1-81.
39. RBS. TB Breathalyser - TB Breath Test. <http://www.rapidbiosensor.com/tbbreathalyser>
40. Institute CaLS. Laboratory Detection and Identification of Mycobacteria, 2nd Edition. M48. Wayne, PA: Clinical and Laboratory Standards Institute.; 2018.
41. Woods GL, Lin S-YG, Desmond EP. Susceptibility Test Methods: Mycobacteria, Nocardia, and Other Actinomycetes. *Manual of Clinical Microbiology, Eleventh Edition*. ASM; 2015.
42. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. *Journal of clinical microbiology*. 2004;42(5):2321-5.
43. Bourgi K, Patel J, Samuel L, Kieca A, Johnson L, Alangaden G. Clinical Impact of Nucleic Acid Amplification Testing in the Diagnosis of Mycobacterium Tuberculosis: A 10-Year Longitudinal Study. *Open forum infectious diseases*. 2017;4(2):ofx045. doi:10.1093/ofid/ofx045
44. Shah M, Martinson NA, Chaisson RE, Martin DJ, Variava E, Dorman SE. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. *Journal of clinical microbiology*. 2010;48(8):2972-4. doi:10.1128/jcm.00363-10
45. Nakiyingi L, Moodley VM, Manabe YC, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. *Journal of acquired immune deficiency syndromes (1999)*. 2014;66(3):270-9. doi:10.1097/qai.0000000000000151
46. Shah M, Hanrahan C, Wang ZY, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. *The Cochrane database of systematic reviews*. 2016;(5):Cd011420. doi:10.1002/14651858.CD011420.pub2
47. WHO. Guidelines on the Management of Latent Tuberculosis Infection. <https://www.ncbi.nlm.nih.gov/books/NBK293809/>
48. Gupta-Wright A, Corbett EL, van Oosterhout JJ, et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. *Lancet (London, England)*. 2018;392(10144):292-301. doi:10.1016/s0140-6736(18)31267-4
49. De Groote MA, Sterling DG, Hraha T, et al. Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis. *Journal of clinical microbiology*. 2017;55(10):3057-3071. doi:10.1128/jcm.00467-17

Reimbursement Policy

50. Heyckendorf J, Andres S, Köser CU, et al. What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. *Antimicrob Agents Chemother*. 2018;62(2)doi:10.1128/aac.01550-17
51. Ustinova VV, Smirnova TG, Sochivko DG, et al. New assay to diagnose and differentiate between Mycobacterium tuberculosis complex and nontuberculous mycobacteria. *Tuberculosis (Edinburgh, Scotland)*. 2019;114:17-23. doi:10.1016/j.tube.2018.10.004
52. Adams S, Ehrlich R, Baatjies R, Dendukuri N, Wang Z, Dheda K. Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting. *Int J Environ Res Public Health*. Aug 14 2019;16(16)doi:10.3390/ijerph16162912
53. Zürcher K, Ballif M, Fenner L, et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. *The Lancet Infectious diseases*. 2019;19(3):298-307. doi:10.1016/s1473-3099(18)30673-x
54. Jain J, Jadhao P, Banait S, Salunkhe P. Diagnostic accuracy of GeneXpert MTB/RIF assay for detection of tubercular pleural effusion. *PloS one*. 2021;16(6):e0251618. doi:10.1371/journal.pone.0251618
55. Karthek V, Bhilare P, Hadgaonkar S, et al. Gene Xpert/MTB RIF assay for spinal tuberculosis- sensitivity, specificity and clinical utility. *J Clin Orthop Trauma*. May 2021;16:233-238. doi:10.1016/j.jcot.2021.02.006
56. Medina-Marino A, Bezuidenhout D, Bezuidenhout C, et al. In-home TB Testing Using GeneXpert Edge is Acceptable, Feasible, and Improves the Proportion of Symptomatic Household Contacts Tested for TB: A Proof-of-Concept Study. *Open forum infectious diseases*. 2024;11(6):ofae279. doi:10.1093/ofid/ofae279
57. CDC. Clinical Testing and Diagnosis for Tuberculosis. Updated April 17, 2025. <https://www.cdc.gov/tb/hcp/testing-diagnosis/index.html>
58. WHO. Implementing Tuberculosis Diagnostics. https://iris.who.int/bitstream/handle/10665/162712/9789241508612_eng.pdf
59. WHO. Latent TB Infection : Updated and consolidated guidelines for programmatic management. <https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf>
60. WHO. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection, 2021 update. <https://www.who.int/publications/i/item/9789240029415>
61. NIH. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Mycobacterium tuberculosis Infection and Disease. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/mycobacterium-0>
62. Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. *American journal of respiratory and critical care medicine*. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST

Reimbursement Policy

63. USPSTF, Mangione CM, Barry MJ, et al. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2023;329(17):1487-1494. doi:10.1001/jama.2023.4899
64. Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2024;doi:10.1093/cid/ciae104
65. AAP. *Red Book® 2021-2024: Report of the Committee on Infectious Diseases, 32nd Edition*. 2021.
66. Domínguez J, Boettger EC, Cirillo D, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. *The International Journal of Tuberculosis and Lung Disease*. 2016;20(1):24-42. doi:10.5588/ijtld.15.0221
67. NICE. Tuberculosis. <https://www.nice.org.uk/guidance/ng33/chapter/Recommendations>
68. ERS/ECDC. ERS/ECDC Statement: European Union Standards for Tuberculosis Care - 2017 update <https://www.ecdc.europa.eu/sites/default/files/documents/ESTC-leaflet-September-2018.pdf>
69. NSTC. Testing and Treatment of Latent Tuberculosis Infection in the United States. https://tbcontrollers.org/docs/NSTC/LTBI_Clinical_Guide_Feb2025_FINAL.pdf
70. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. *J Am Acad Dermatol*. 2008;59(2):209-17. doi:10.1016/j.jaad.2008.03.023

VI. Revision History

Revision Date	Summary of Changes
09/04/2025	Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria: Direct probe testing is no longer available. This results in removal of CC3 and qualitative NAAT testing becomes CC2.c.: “c) Qualitative nucleic acid amplification testing (NAAT) for Mycobacteria spp., M. tuberculosis, and M. avium complex.” Former CC4, now CC3, replaced “Hologic Amplified MTD” with “NAAT” for clarity. Removed CC9. With removal of direct probes, there is no situation in which two types of NAAT would be allowed, making CC9 redundant.

Reimbursement Policy

	Former CC10, now CC8 updated “M. avium intracellulare” to “M. avium complex” to align with updated naming convention Removed CPT code 87149, 87550, 87555, 87560
06/04/2025	Off-cycle coding modification: Added CPT code 0574U (effective date 7/1/2025)
12/04/2024	Off-cycle coding modification: Added CPT code 87564 (effective date 1/1/2025)